SOUL trial preliminary data — semaglutide in T2DM cardiovascular outcomes

Let me address the comparison question directly. There's a temptation to compare SOUL (oral sema 14mg, HR 0.86) unfavorably against SELECT (SC sema 2.4mg, HR 0.80). But that comparison is deeply flawed for several reasons:

1. Different populations: SOUL enrolled T2DM patients; SELECT enrolled non-diabetic obesity patients with established CVD. Diabetes itself modifies the CV risk profile and response to interventions.
2. Different doses: Oral sema 14mg achieves plasma semaglutide exposures roughly equivalent to SC sema 0.5-1.0mg, NOT 2.4mg. This is a pharmacokinetics issue — oral bioavailability of semaglutide with SNAC is only ~1%. The 14mg oral dose was the maximum approved for T2DM when SOUL was designed.
3. Different background therapy: SOUL patients were on more intensive glucose-lowering therapy at baseline, including some on SGLT2 inhibitors (which themselves have CV benefit). Incremental benefit on top of SGLT2i is harder to demonstrate.
4. Different follow-up: SOUL had longer follow-up (~4 years vs ~3.3 years), which matters for time-dependent hazard ratios.

The more relevant comparison is SOUL vs LEADER (liraglutide CVOT): LEADER showed HR 0.87 for 3P-MACE, almost identical to SOUL's 0.86. Given that liraglutide and oral semaglutide 14mg achieve similar GLP-1R engagement levels, this consistency is pharmacologically reassuring.[2]

The oral bioavailability issue deserves deeper exploration because it has major implications for the future.

Current oral semaglutide (Rybelsus) uses the SNAC absorption enhancer (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate), which locally and transiently raises gastric pH and promotes transcellular absorption in the stomach. Even with SNAC, absolute bioavailability is approximately 0.4-1.0%, with enormous inter- and intra-individual variability (CV% for Cmax ~80-100%).[3]

This means that oral sema 14mg gives exposure equivalent to roughly SC sema 0.5-1.0mg. To achieve exposure equivalent to SC sema 2.4mg (the obesity dose), you'd theoretically need oral doses of ~50-70mg, which raises concerns about SNAC-related GI effects and cost.

Novo has been developing higher oral sema doses (25mg and 50mg) with improved formulations. Phase 3 data for oral sema 50mg in obesity (OASIS trials) showed ~17% weight loss at 68 weeks — getting closer to injectable performance but still somewhat lower.[4]

SOUL used the 14mg dose because that's what was approved when the trial was designed. The higher oral doses weren't available. So in some sense, SOUL demonstrates CV benefit with a "subtherapeutic" dose relative to what we now know is achievable orally.

From a clinical practice standpoint, SOUL is hugely important for one simple reason: many patients refuse injections. Full stop. I have patients who are appropriate candidates for GLP-1 RAs but will not consider a weekly subcutaneous injection under any circumstances — needle phobia, convenience concerns, perceived stigma.

Before SOUL, I could offer these patients oral semaglutide for glycemic control but couldn't cite a CVOT for cardiovascular benefit with the oral formulation. Now I can. This changes the conversation.

Practical challenges with oral sema that SOUL doesn't address:

• Must be taken fasting with <=4 oz water, 30 min before eating — adherence to dosing instructions is poor in real-world settings
• Drug interactions with PPIs (reduce absorption) — many T2DM/CVD patients are on PPIs
• Highly variable absorption means some patients get excellent exposure and others get minimal
• The 14mg dose provides less weight loss than SC 2.4mg, which matters for patients with dual obesity/CVD indications

I'm hoping the next-gen oral formulations (higher doses, improved absorption technology) will solve some of these issues. But for now, having CVOT data for the oral formulation is a significant clinical win.

Can someone explain what a CVOT actually is and why it matters so much? I keep seeing the term but I'm not clear on why it's such a big deal for a diabetes drug to have one.